Status: Recruiting
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
The goal of this interventional clinical study is to learn the safety and preliminary efficacy of XH001 injection (Personalized mRNA tumor neoantigen vaccine) combined with standard adjuvant treatment in treating patients with high-risk recurrent solid tumors after radical surgery. The main questions it aims to answer are: What medical problems do participants have when using the combined treatment? Does XH001 injection combined with standard adjuvant treatment induce a specific T-cell response, and can it prolong the patient's relapse-free survival?
Participants needed: 48
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: Shenzhen Xinhe BiomedicalUpdated: May 19, 2026Locations: 2
Eligibility criteria
Provision of signed and dated informed consent form; [+5]
There is evidence of tumor residue, recurrence or metastasis during screening; [+13]